ViroGates publishes prospectus for its initial public offering in Copenhagen.

ViroGates intends to strengthen its capital structure to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage.

Meet us at SEMES Emergency Conference in Toledo, Spain and hear about suPARnostic®!


ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.

Please welcome Thomas Krarup who has joined ViroGates as new VP Sales & Marketing.

Thomas' educational background includes a PhD in biology from Copenhagen University, Denmark, and Syracuse University, USA.

Kidney Disease and The Heart: Is suPAR the Missing Link?

Sunday, March 11, 10:45 a.m. – 12:15 p.m.
Presented by Salim Hayek, MD